Global Axial Spondyloarthritis (axSpA) - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026 - 2031)

According to Mordor Intelligence, the axial spondyloarthritis market size was valued at USD 4.39 billion in 2025 and estimated to grow from USD 4.68 billion in 2026 to reach USD 6.46 billion by 2031, at a CAGR of 6.66% during the forecast period (2026-2031).

This report is Segmented by Disease Types (Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis), by Drug Class (NSAIDs, Glucocorticoids, and More), Route of Administration (Oral, Subcutaneous, and More), Distribution Channel (Hospital Pharmacies, and More), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Axial Spondyloarthritis (axSpA) Market Trends and Insights

Rising diagnosis rates due to MRI advocacy programs

Updated ASAS classification and insurance alignment have cut diagnostic delay from more than eight years to roughly three in centers that mandate MRI for early back-pain evaluation. Enhanced Dixon sequencing now reaches 96% diagnostic accuracy, unlocking larger treatable populations and fueling the axial spondyloarthritis market. Early identification also prevents structural damage and supports long-term work productivity, strengthening payers' cost-saving arguments.

Rapid uptake of IL-17 & JAK inhibitors in treatment guidelines

The 2022 ASAS/EULAR recommendations promoted IL-17 and JAK inhibitors once NSAIDs and at least one TNF blocker fail. Bimekizumab, approved in 2024, delivered ASAS40 responses above 44%, setting a new efficacy bar and providing the first dual cytokine blockade option. Upadacitinib and other JAK agents broaden oral alternatives despite cardiovascular warnings, enlarging the axial spondyloarthritis market as second-line therapy is standardized.

Persistently high treatment costs of novel biologics

Bimekizumab's USD 8,281 per injection illustrates ongoing affordability barriers despite biosimilar rivalry. Total annual therapy outlays hover near USD 10,000, straining payer budgets and limiting uptake in lower-income settings. Added monitoring, administration overhead, and adverse-event management inflate economic burden and temper the axial spondyloarthritis market's fullest potential.

Other drivers and restraints analyzed in the detailed report include:

1. Expansion of biosimilar TNF-a inhibitors improves affordability
2. Growing employer-sponsored specialty pharmacy benefits
3. Limited long-term safety data for JAK inhibitors

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Ankylosing spondylitis led revenue with 66.92% share in 2025, yet non-radiographic presentations are rising at a 7.69% CAGR to 2031. Early MRI adoption now picks up inflammatory lesions before structural damage, swelling the non-radiographic patient base inside the axial spondyloarthritis market. Clinical trials report similar biologic response rates for both phenotypes, validating aggressive treatment earlier in the disease course. Inter-regional contrasts are pronounced; Asian cohorts show just 14.4% non-radiographic incidence, half that of Western peers, reflecting divergent genetics and care accessibility. Harmonized nomenclature and ASAS criteria continue to raise awareness, sustaining double-digit gains for diagnostically driven volumes and enlarging axial spondyloarthritis market opportunity across all drug classes.

Elevated research interest centers on biomarkers that predict radiographic conversion, aiming to target therapy before irreversible fusion. Commercial upside lies in companion diagnostics that would differentiate aggressiveness, potentially justifying premium pricing. Education campaigns by patient groups further speed recognition, while tele-rheumatology may shrink urban-rural gaps, reinforcing structural tailwinds that support prolonged segment expansion within the axial spondyloarthritis market.

DMARDs represented 49.02% of global revenue in 2025 and are set for 7.11% CAGR, propelled by biologic and targeted synthetic launches. Dual IL-17 inhibition through bimekizumab augments this category, offering superior ASAS40 outcomes. JAK agents deepen flexibility, though monitoring demands persist. The axial spondyloarthritis market size for DMARDs is forecast to climb steadily as real-world data strengthen payer confidence and formulary positions broaden.

NSAIDs and glucocorticoids remain crucial for symptom flare control but face stagnant growth, mainly due to gastrointestinal and bone-density risk profiles. Novel entrants like NLRX1 agonists and microbiome modulators promise to diversify mechanisms, ensuring continuous pipeline replenishment. Observational registries will likely influence guideline placement, particularly if newer molecules prove durable with clean long-term safety signatures, thus safeguarding DMARD dominance inside the axial spondyloarthritis market.

Complete Report Scope:

• By Disease Type
  • Ankylosing Spondylitis (Radiographic axSpA)
  • Non-radiographic Axial Spondyloarthritis
• By Drug Class
  • Non-steroidal Anti-inflammatory Drugs (NSAIDs)
  • Glucocorticoids
  • Disease-modifying Antirheumatic Drugs (DMARDs)
  • Others
• By Route of Administration
  • Oral
  • Subcutaneous
  • Intravenous
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America anchors 39.78% of global revenue and benefits from high biologic penetration, employer-funded specialty benefits, and streamlined FDA approval pathways. MRI density and AI-enabled reading tools have trimmed average diagnostic latency to 2.7 years, amplifying treated prevalence. Biosimilar diffusion is reshaping rebates and opening space for novel agents without swelling payer budgets, sustaining revenue leadership across the axial spondyloarthritis market.

Asia-Pacific records the quickest 7.19% CAGR through 2031 as China broadens reimbursement and hospital capacity. Ankylosing spondylitis prevalence of up to 0.42% implies sizable underdiagnosis. Japan exhibits high biologic utilization tied to universal coverage, whereas India still struggles with specialist scarcity and out-of-pocket limits. Regional public-private projects to add MRI scanners and tele-rheumatology services will likely raise drug volumes. Cultural integration of yoga and Tai Chi into standard care underscores local adaptation in managing axial disease.

Europe remains a mature market with universal coverage, but access variability lingers. Central and Eastern states lag in biologic uptake (27.9%) and endure longer diagnostic delays (4.2 years), muting growth. The continent nevertheless pioneers biosimilar policy, fostering competitive pricing. Middle East & Africa trail, constrained by fiscal capacity and cold-chain gaps, yet targeted donor programs and urban clinic build-outs are stirring incremental demand. South America offers mid-single-digit expansion tempered by macroeconomic volatility and reimbursement lag.

1. Abbvie
2. Johnson & Johnson
3. Novartis
4. Pfizer
5. Eli Lilly and Company
6. Amgen
7. UCB
8. Kyowa Kirin
9. Acelyrin
10. Bristol-Myers Squibb
11. Biogen
12. Samsung Bioepis
13. Celltrion Healthcare
14. Gilead Sciences
15. Fresenius
16. Sun Pharmaceuticals Industries
17. Lupin
18. Dr. Reddy's Laboratories
19. Sandoz Group
20. Sanofi
21. Roche
22. Boehringer Ingelheim
23. Takeda Pharmaceuticals
24. Galapagos NV

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support